Jesus M. Ontoria

Rome, 00071, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Discovery and Optimization of IRBM-Z-2, an Allosteric Zika Virus NS2B-NS3 Protease Inhibitor Exhibiting In Vivo Efficacy.

Discovery and Optimization of IRBM-Z-2, an Allosteric Zika Virus NS2B-NS3 Protease Inhibitor Exhibiting In Vivo Efficacy.

Journal: Journal of medicinal chemistry

Published: May 29, 2026

An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse models.

An allosteric inhibitor of the Zika virus NS2B-NS3 protease with oral efficacy in mouse models.

Journal: Nature communications

Published: May 15, 2025

Direct-to-biology platform: From synthesis to biological evaluation of SHP2 allosteric inhibitors.

Direct-to-biology platform: From synthesis to biological evaluation of SHP2 allosteric inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: December 22, 2023

Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors.

Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors.

Journal: ACS medicinal chemistry letters

Published: October 21, 2022

SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease.

SAR evolution towards potent C-terminal carboxamide peptide inhibitors of Zika virus NS2B-NS3 protease.

Journal: Bioorganic & medicinal chemistry

Published: July 30, 2021

Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT.

Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT.

Journal: Bioorganic & medicinal chemistry letters

Published: February 24, 2020

Discovery of 4-((1-(1H-imidazol-2-yl)alkoxy)methyl)pyridines as a new class of Trypanosoma cruzi growth inhibitors.

Discovery of 4-((1-(1H-imidazol-2-yl)alkoxy)methyl)pyridines as a new class of Trypanosoma cruzi growth inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: January 13, 2020

Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction.

Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction.

Journal: ACS medicinal chemistry letters

Published: December 11, 2019

Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.

Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.

Journal: ACS medicinal chemistry letters

Published: October 31, 2018

Discovery of 2-(1H-imidazo-2-yl)piperazines as a new class of potent and non-cytotoxic inhibitors of Trypanosoma brucei growth in vitro.

Discovery of 2-(1H-imidazo-2-yl)piperazines as a new class of potent and non-cytotoxic inhibitors of Trypanosoma brucei growth in vitro.

Journal: Bioorganic & medicinal chemistry letters

Published: September 25, 2018

Discovery of a Selective Series of Inhibitors of Plasmodium falciparum HDACs.

Discovery of a Selective Series of Inhibitors of Plasmodium falciparum HDACs.

Journal: ACS medicinal chemistry letters

Published: December 07, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026